What is HC Wainwright’s Forecast for DMAC FY2026 Earnings?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Free Report) – Equities research analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of DiaMedica Therapeutics in a research note issued on Monday, November 16th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.81) per share for the year, down from their prior forecast of ($0.80). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q4 2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at ($0.65) EPS and FY2029 earnings at ($0.28) EPS.

Several other research analysts also recently issued reports on DMAC. Wall Street Zen downgraded DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $12.00.

Read Our Latest Stock Report on DiaMedica Therapeutics

DiaMedica Therapeutics Trading Down 6.6%

Shares of DMAC stock opened at $8.02 on Wednesday. The firm has a market capitalization of $432.76 million, a price-to-earnings ratio of -10.55 and a beta of 0.95. The business’s 50-day moving average price is $8.35 and its 200-day moving average price is $7.20. DiaMedica Therapeutics has a 12 month low of $5.24 and a 12 month high of $11.00.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21).

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Private Capital Management LLC lifted its stake in shares of DiaMedica Therapeutics by 20.0% in the 3rd quarter. Private Capital Management LLC now owns 60,000 shares of the company’s stock valued at $496,000 after purchasing an additional 10,000 shares during the period. Goldman Sachs Group Inc. grew its stake in DiaMedica Therapeutics by 11.5% during the third quarter. Goldman Sachs Group Inc. now owns 187,465 shares of the company’s stock worth $1,550,000 after purchasing an additional 19,399 shares during the period. Cetera Investment Advisers acquired a new stake in DiaMedica Therapeutics during the third quarter worth approximately $280,000. AWM Investment Company Inc. grew its stake in DiaMedica Therapeutics by 80.8% during the third quarter. AWM Investment Company Inc. now owns 65,097 shares of the company’s stock worth $538,000 after purchasing an additional 29,097 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new stake in DiaMedica Therapeutics in the third quarter worth approximately $332,000. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.

Read More

Earnings History and Estimates for DiaMedica Therapeutics (NASDAQ:DMAC)

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.